Show simple item record

dc.contributor.authorFarahmand, F
dc.contributor.authorMohammadi, T
dc.contributor.authorNajafi, M
dc.contributor.authorFallahi, G
dc.contributor.authorKhodadad, A
dc.contributor.authorMotamed, F
dc.contributor.authorMarashi, SM
dc.contributor.authorShoaran, M
dc.contributor.authorRafsanjani, RN
dc.date.accessioned2018-08-26T08:50:53Z
dc.date.available2018-08-26T08:50:53Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53129
dc.description.abstractHelicobacter pylori infection is a prevalent disease among Iranian children. The purpose of this study was to compare the effect of ciprofloxacin and furazolidone on eradicating helicobacter pylori in Iranian children in combination with amoxicillin and omeprazole. In this cohort study, helicobacter pylori infection was confirmed by gastroscopy, rapid urease test or pathologic assessments. A total of 66 children were randomly enrolled; based on the random number table, and were divided into two groups; first, a combination regimen consisting of ciprofloxacin, amoxicillin, and omeprazole; second, a three-medication regimen consisting of amoxicillin, furazolidone, and omeprazole. The effect of both medical regimens on the successful eradication of helicobacter pylori infection was assessed and compared. Chi-square test was used for evaluating the association between quantitative variables. All comparisons were made at the significance of P<0.05. Endoscopic tests prior to initiating treatments showed that 66.7% of the patients had a degree of nodularity while peptic ulcer was only observed in one patient. One month after the end of the treatments, eradication of the helicobacter pylori infection was reported 87.9% (29/33) in the first group (CAO) and 60.6% (20.33) in the second group (FAO) (P=0.011). It appears that a major advantage of our proposed regimen over others is a lack of wide use of fluoroquinolones for treating children's diseases. Given FDA's recommendation about the possibility of prescribing ciprofloxacin for infected patients with multidrug resistance, we can use the regimen proposed in this study in patients with resistance to standard treatments. é 2016 Tehran University of Medical Sciences. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofActa Medica Iranica
dc.subjectamoxicillin
dc.subjectciprofloxacin
dc.subjectfurazolidone
dc.subjectomeprazole
dc.subjectamoxicillin
dc.subjectantiinfective agent
dc.subjectciprofloxacin
dc.subjectfurazolidone
dc.subjectabdominal pain
dc.subjectadolescent
dc.subjectanemia
dc.subjectArticle
dc.subjectbleeding
dc.subjectchild
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectdisease eradication
dc.subjectduodenum ulcer
dc.subjectendoscopy
dc.subjectfeces analysis
dc.subjectfemale
dc.subjectgastroscopy
dc.subjectHelicobacter infection
dc.subjecthuman
dc.subjectiron deficiency
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectquestionnaire
dc.subjectrandomized controlled trial
dc.subjectrapid urease test
dc.subjectsingle drug dose
dc.subjecttreatment outcome
dc.subjectvomiting
dc.subjectcombination drug therapy
dc.subjectdose response
dc.subjectdrug effects
dc.subjectHelicobacter Infections
dc.subjectHelicobacter pylori
dc.subjectisolation and purification
dc.subjectmicrobiology
dc.subjectAmoxicillin
dc.subjectAnti-Bacterial Agents
dc.subjectChild
dc.subjectCiprofloxacin
dc.subjectDose-Response Relationship, Drug
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectFurazolidone
dc.subjectHelicobacter Infections
dc.subjectHelicobacter pylori
dc.subjectHumans
dc.subjectMale
dc.subjectTreatment Outcome
dc.titleComparison of ciprofloxacin-based triple therapy with conventional triple regimen for Helicobacter pylori eradication in children
dc.typeReview
dc.citation.volume54
dc.citation.issue6
dc.citation.spage395
dc.citation.epage400
dc.citation.indexScopus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record